| Literature DB >> 31877815 |
Mihaela Cudalbeanu1, Bianca Furdui1, Geta Cârâc1, Vasilica Barbu2, Alina Viorica Iancu3, Fernanda Marques4, Jorge Humberto Leitão5, Sílvia Andreia Sousa5, Rodica Mihaela Dinica1.
Abstract
This study aimed to explore for the first time the biological properties such as antifungal, antitumoral and antioxidant of Danube Delta Nymphaea alba (N. alba) leaf and root methanolic extracts. The toxicity studies of N. alba extracts showed no inhibitory effect on wheat seed germination by evaluating the most sensitive physiological parameters (Germination %, Germination index, Vigor index) and using confocal laser scanning microscopy images. The analyzed extracts were found to have high antifungal activity against Candida glabrata with MIC values of 1.717 µg/mL for leaf and 1.935 µg/mL for root. The antitumor activity of the both extracts against A2780/A2780cisR ovarian, LNCaP prostate and MCF-7 breast cancer cells was promising with IC50 values ranging from 23-274 µg/mL for leaf and 18-152 µg/mL for root, and the combination of N. alba extracts with cisplatin showed a synergistic effect (coefficient of drug interaction <1). The antioxidant properties were assessed by β-carotene bleaching, ABTS and FRAP assays and cyclic voltammetry. Quercetin, the most prominent antioxidant, was quantified in very good yields by spectroelectrochemical assay.Entities:
Keywords: Nymphaea alba; antifungal activity; antioxidant compounds; antitumor activity; quercetin
Year: 2019 PMID: 31877815 PMCID: PMC7168328 DOI: 10.3390/antibiotics9010007
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Nymphaea alba.
Evaluation of different physiological parameters of wheat seed germination on treatment with N. alba extracts. Results are expressed as mean values ± standard deviation.
| Physiological Parameters * | Concentration of the | Control | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Leaf | Root | ||||||||
| 10 | 100 | 500 | 1000 | 10 | 100 | 500 | 1000 | ||
|
| 94.2 ± 0.24 | 94.6 ± 0.40 | 95.9 ± 0.91 | 97.4 ± 0.50 | 94.7 ± 0.52 | 96 ± 0.37 | 96 ± 0.15 | 97.4 ± 1.00 | 100 ± 0.00 |
|
| 84.60 ± 1.20 | 101.13 ± 0.87 | 103.43 ± 1.13 | 103.55 ± 0.97 | 69.09 ± 0.73 | 91.76 ± 1.00 | 94.55 ± 0.76 | 100.07 ± 0.45 | 100 ± 0.00 |
|
| 1.1 ± 0.10 | 0.9 ± 0.20 | 0.9 ± 0.25 | 0.9 ± 0.14 | 1.4 ± 0.10 | 1.0 ± 0.21 | 1.0 ± 0.50 | 1.0 ± 0.45 | 1.0 ± 0.00 |
|
| 120.2 ± 0.43 | 146.2 ± 0.35 | 117.9 ± 0.10 | 113.8 ± 0.10 | 89.5 ± 0.24 | 137.6 ± 0.17 | 92.9 ± 0.24 | 123.7 ± 0.13 | 66.6 ± 0.14 |
|
| 0.8 ± 0.12 | 0.6 ± 0.12 | 0.5 ± 0.24 | 0.6 ± 0.10 | 0.7 ± 0.43 | 0.5 ± 0.12 | 0.5 ± 0.11 | 0.8 ± 0.10 | 1.0 + 0.00 |
* G%—germination percentage; RRG%—relative root growth percentage; GI—germination index; VI—vigor index; TI—tolerance index.
Figure 2Confocal laser scanning microscopy images of the wheat sprout sections variants: (a) ultrapure water control samples; and (b) methanol control samples.
Figure 3Confocal laser scanning microscopy images of the wheat shoot sections variants of the N. alba leaf extract treatments: (a) 10 µg/mL, (b) 100 µg/mL, (c) 500 µg/mL, and (d) 1000 µg/mL.
Figure 4Confocal laser scanning microscopy images of the wheat shoot sections variants of the N. alba root extract treatments: (a) 10 µg/mL, (b) 100 µg/mL, (c) 500 µg/mL, and (d) 1000 µg/mL.
Figure 5The MIC of the N. alba leaf (a) and root (b) extracts and fluconazole (c) against C. glabrata CBS 138.
Figure 6CFUs of C. glabrata CBS 138 strain, cultured in the presence of the indicated concentrations of the N. alba leaf and root (a) extracts and fluconazole (b).
Figure 7In vitro cytotoxicity assessment of N. alba leaf and root extracts on A2780 (a), LNCaP (b), MCF7 (c), and V79 (d) cell lines.
IC50 values of N. alba extracts obtained after 24 h incubation. Data were obtained from dose-response curves using GraphPad Prism ver. 5. The results are expressed in µg/mL.
| Tumor Cells * | ||||
|---|---|---|---|---|
| V79 | A2780 | LNCaP | MCF-7 | |
|
| 367 ± 50 | 23.2 ± 3.0 | 274 ± 81 | 25.4 ± 5.9 |
|
| 281 ± 59 | 19.4 ± 3.8 | 152 ± 47 | 18.1 ± 3.3 |
* V79—lung fibroblasts normal cells; A2780—ovarian tumor cells; LNCaP—prostate tumor cells; MCF-7—tumor breast cells.
Figure 8In vitro cytotoxicity assessment of cisplatin on A2780 (a) and A2780 cisR (b) cell lines. The IC50 values found using the GraphPad Prism software (ver. 5) were: A2780, 2.4 ± 0.6 µg/mL (7.9 µM) and A2780cisR, 27 ± 13 µg/mL (89 µM). Control = cells without treatment. Data are mean ± SD of two independent experiments done with at least four replicates per condition.
Interaction between N. alba extracts and cisplatin on the A2780 and A2780cisR cancer cell lines. Fa is the fraction affected by dose; CI is the combination index.
| Drug (µg/mL) | A2780 * | A2780cisR * | |||
|---|---|---|---|---|---|
|
|
|
|
|
|
|
| 1000 | 100 | 0.03 | 4.85 | 0.12 | 1.20 |
| 500 | 50 | 0.01 | 1.03 | 0.10 | 0.44 |
| 200 | 20 | 0.04 | 1.22 | 0.06 | 0.08 |
| 100 | 10 | 0.02 | 0.35 | 0.07 | 0.05 |
| 10 | 1 | 0.70 | 2.07 | 0.60 | 0.57 |
|
|
|
|
|
|
|
| 1000 | 100 | 0.10 | 12.59 | 0.25 | 2.81 |
| 500 | 50 | 0.12 | 7.64 | 0.32 | 2.28 |
| 200 | 20 | 0.09 | 2.25 | 0.17 | 0.30 |
| 100 | 10 | 0.12 | 1.52 | 0.26 | 0.30 |
| 10 | 1 | 0.69 | 2.25 | 0.89 | 10.03 |
* A2780—ovarian tumor cells; A2780cisR—ovarian tumor cisplatin-resistant cells. Cisplatin = CisPt
Antioxidant activity of N. alba extracts determined by BCB, ABTS and FRAP assays.
| Assay * | ||||||
|---|---|---|---|---|---|---|
| Leaf | Root | |||||
| Inhibition Percent (%) | IC50 (µg/mL) | µg TEq/1 g | Inhibition Percent (%) | IC50 (µg/mL) | µg TEq/1 g | |
|
| 78.6 ± 0.19 | 33 ± 0.86 | 28,933 ± 0.89 | 90.1 ± 0.90 | 21 ± 0.55 | 79,371 ± 1.03 |
|
| 77.0 ± 0.73 | 12 ± 0.11 | 1309 ± 0.33 | 78.2 ± 0.12 | 10 ± 0.10 | 1950 ± 0.41 |
|
| 74.6 ± 0.13 | 30 ± 0.25 | 2245 ± 0.67 | 79.7 ± 0.13 | 13 ± 0.15 | 2407 ± 0.98 |
* BCB—β-Carotene bleaching; ABTS—2,20-azinobis (3-ethylbenothiazoline-6-sulfonic acid) diammonium salt solution radical cation; FRAP—Ferric Reducing Antioxidant Power.
Figure 9Cyclic voltammograms recorded for the N. alba leaf (1) and root (2) extracts compared with quercetin (blue line). E = ± 1 V vs. Ag/AgClsat., scan rate of 100 mV s−1 (a). Dependence of the anodic current vs square root of the scan rates (b).
Figure 10UV-VIS spectra recorded for the N. alba leaf and root methanolic extracts before (a) and after cyclic voltammetry experiments (b).
Figure 11The LC-MS/MS chromatographic separation of the methanolic N. alba leaf extract (H-HHDP-hexoside, Qu–quinic acid, C–corilagin, V–vanillic acid, Cas–castalin, Ga–gallic acid, G–geraniin, Ca–caffeic acid, p-C–coumaric acid, T–tannic acid, R–rutin, El–ellagic acid, Elr–ellagic rhamnosyl acid, Elp–ellagic pentoside acid, Cn–cinnamic acid derivative, Na–naringenin, N–naringin, Ch–catechin, Ep–epicatechin, Cl–chlorogenic acid, Q–quercetin, L–luteolin, B–brevifolin, O–orientin).
Identified compounds from N. alba leaf and root extracts and their biological properties.
| No. | Identified Compounds from | Biologic Properties | References |
|---|---|---|---|
|
| HHDP-hexoside | antioxidant, anti-inflammatory, antitumor, and apoptotic properties; antibacterial activity against | [ |
|
| Quinic acid | induces cancer cell death by modulating the expression of Akt, phospho-Akt, and cell cycle pathway; anti-prostate cancer, attenuates Alzheimer’s disease | [ |
|
| Vanillic acid | antibacterial, antioxidant and antihypertensive activities, α-glucosidase and tyrosinase inhibitory, effects against dextran sulfate sodium (DSS)-induced ulcerative colitis | [ |
|
| Gallic acid | antiviral and antioxidant activities, anticancer activity by inducing apoptosis, downregulating genes involved in cell cycle and angiogenesis, and stimulating a cellular immune response | [ |
|
| Castalin | antimicrobial, anti-inflammatory | [ |
|
| Chlorogenic acid | inhibiting gene β-catenin and inducting genes GSK-3β, antispasmodic and antioxidant activities, inhibition of the HIV-1 integrase and inhibition of the mutagenicity of carcinogenic compounds | [ |
|
| Corilagin | anticancer, anti-hyperalgesic, antioxidant, anti-inflammatory, hepatoprotective, and antitumor actions, induced apoptosis and autophagic cell death | [ |
|
| Brevifolin | antioxidant, anti-inflammatory and anticancer | [ |
|
| Caffeic acid | inhibiting gene β-catenin and inducting genes GSK-3β, antispasmodic and antioxidant activities | [ |
|
| p-Coumaric acid | anti-inflammatory, anti-tyrosinase and antimicrobial activities, antispasmodic and antioxidant activities | [ |
|
| Tannic acid | anticancer activity by inducing apoptosis, downregulating genes involved in cell cycle and angiogenesis, and stimulating a cellular immune response, Antioxidant and α-amylase inhibitory activities | [ |
|
| Rutin | antioxidant activity, apoptosis, down regulating genes involved in cell cycle and angiogenesis antimetastatic, induces glutathione and glutathione peroxidase activities | [ |
|
| Ellagic acid | anticancer activity by inducing apoptosis, downregulating genes involved in cell cycle and angiogenesis, and stimulating a cellular immune response; antioxidant and antiviral activities, inhibit α-glucosidase and α-amylase | [ |
|
| Ellagic acid rhamnosyl | anticancer activity by inducing apoptosis, downregulating genes involved in cell cycle and angiogenesis, and stimulating a cellular immune response | [ |
|
| Quercetin | apoptosis, down regulating genes involved in cell cycle and angiogenesis inhibited melanoma cell inhibits development of | [ |
|
| Ellagic acid-pentoside | anticancer activity by inducing apoptosis, downregulating genes involved in cell cycle and angiogenesis, and stimulating a cellular immune response, antioxidant activity | [ |
|
| Naringenin | anticancer effect arrests cell development at the G0/G1 phase; inhibits | [ |
|
| Naringin | anticancer effect arrests cell development at the G0/G1 phase; inhibits | [ |
|
| Luteolin | anticancer associated with the induction of apoptosis, and inhibition of cell proliferation, metastasis and angiogenesis | [ |
|
| Ferulic acid | synergistic effects against | [ |
|
| Cinnamic acid derivative | anti-inflammatory, anti-tyrosinase and antimicrobial activities | [ |
|
| Catechin | anticancer activity | [ |
|
| Epicatechin | anticancer activity | [ |
|
| Apigenin | anticancer effect by arresting cell development at the G0/G1 phase; the inhibition of phosphorylation of mitogen-activated protein kinase (MAPK) | [ |
|
| Orientin | antioxidant, antiviral and antibacterial activities, anti-inflammatory neuroprotective or antidepressant-like effects | [ |